PhagoMed (now known as BioNTech after buyout), is developing novel synthetic lysin technology for precision antimicrobial treatments.
The Vienna-based biotech company uses lysins, which are enzymes produced by bacteriophages that break down bacterial cell walls and kill bacteria.
PhagoMed’s Lysin Builder platform allows for the development of synthetic lysins that create targeted antibacterials...
